von Eicken J, Höh H, Rehfeldt K
Klinik für Augenheilkunde, Dietrich Bonhoeffer-Klinikum Neubrandenburg, Salvador-Allende-Strasse 30, 17036 Neubrandenburg.
Klin Monbl Augenheilkd. 2007 Feb;224(2):140-5. doi: 10.1055/s-2006-927389.
There are only few reports about the safety of photodynamic therapy (PDT) with verteporfin in secondary neovascularisations and only scarce reports about the PDT in children, only one of them in preschool-age children. We add the case of a 5 and a half-year-old child with choroidal neovascularisation due to choroidal coloboma. We treated this condition with PDT.
A 5 and a half-year-old-child with choroidal coloboma in both eyes showed a switch of fixation from the right to the left eye and divergent strabismus switched to convergent strabismus, in addition a decrease in visual acuity from 0.4 to 0.04 was recorded. This was caused by a clinically visible subfoveal choroidal neovascularisation from the upper edge of the coloboma. Because no standard therapy is available for this special condition, we decided to treat the child with PDT.
PDT with verteporfin was performed without problems after motivation and support of the child by the parents (2.46 mL verteporfin, 4500 microm spot size, 83 seconds treatment time) and led to a complete scaring of the CNV after 14 days. At follow-up 3 and 6 months after therapy we documented only a moderate staining but no fluorescein leakage from the CNV and no macular oedema. Visual acuity increased after occlusion therapy within 24 months to 0.2 and fixation of the treated right eye was restored and resulted in intermittent fixation. Mean while the German "Bundessozialgericht" has decided on the reimbursement rules for this off-label use in very seldom diseases. No recurrence of the CNV was observed within the follow-up time of 5 and a half years.
This case proves that PDT is possible and safe in cooperative children including those in preschool age. PDT not only induced scaring of a CNV secondary to choroidal coloboma but also a return of the lost visual acuity.
关于维替泊芬光动力疗法(PDT)在继发性新生血管形成中的安全性报道较少,关于儿童PDT的报道也很少,其中只有一篇是关于学龄前儿童的。我们补充了一例5岁半因脉络膜缺损导致脉络膜新生血管形成的儿童病例。我们用PDT治疗了这种疾病。
一名双眼患有脉络膜缺损的5岁半儿童,出现注视从右眼转向左眼,斜视从外斜视转为内斜视,此外,视力从0.4下降到0.04。这是由脉络膜缺损上缘临床可见的黄斑下脉络膜新生血管形成引起的。由于针对这种特殊情况没有标准治疗方法,我们决定用PDT治疗该患儿。
在父母对孩子的激励和支持下,顺利进行了维替泊芬PDT治疗(维替泊芬2.46 mL,光斑大小4500微米,治疗时间83秒),14天后脉络膜新生血管完全瘢痕化。在治疗后3个月和6个月的随访中,我们仅记录到中度染色,但脉络膜新生血管没有荧光素渗漏,也没有黄斑水肿。在24个月内进行遮盖治疗后,视力提高到0.2,治疗的右眼恢复注视并导致间歇性注视。同时,德国“联邦社会法院”已就这种罕见疾病的超说明书用药报销规则做出决定。在5年半的随访期内未观察到脉络膜新生血管复发。
该病例证明,PDT对合作的儿童包括学龄前儿童是可行且安全的。PDT不仅使脉络膜缺损继发的脉络膜新生血管形成瘢痕化,还使丧失的视力恢复。